Production (Stage)
X4 Pharmaceuticals, Inc.
XFOR
$3.10
-$0.13-4.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1,908.86% | 156.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1,908.86% | 156.07% | |||
| Cost of Revenue | 1,461.59% | 33.04% | |||
| Gross Profit | 2,028.18% | 239.94% | |||
| SG&A Expenses | -0.82% | -3.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.96% | 5.96% | |||
| Operating Income | 73.56% | -3.52% | |||
| Income Before Tax | 100.80% | -7.86% | |||
| Income Tax Expenses | -86.82% | 1,620.00% | |||
| Earnings from Continuing Operations | 100.71% | -8.52% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 100.71% | -8.52% | |||
| EBIT | 73.56% | -3.52% | |||
| EBITDA | 74.70% | -3.53% | |||
| EPS Basic | 100.70% | -7.41% | |||
| Normalized Basic EPS | 100.79% | -6.76% | |||
| EPS Diluted | 100.68% | -7.41% | |||
| Normalized Diluted EPS | 100.79% | -6.76% | |||
| Average Basic Shares Outstanding | 1.12% | 1.03% | |||
| Average Diluted Shares Outstanding | 1.55% | 1.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||